Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 22, Issue 8, Pages 575-580Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2022.02.008
Keywords
CPX-351; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Induction Chemotherapy
Categories
Ask authors/readers for more resources
AML treatment has evolved with the introduction of CPX-351 as a novel therapeutic approach, showing promise in improving the treatment outcomes for AML patients.
Acute myeloid leukemia (AML) treatment landscape had evolved over the last decades with better understanding of the disease genomics and the use of the targeted therapy, despite this treatment evolution, 7 + 3 remains the mainstay treatment for most AML cases. Many attempts had been made to improve the treatment outcome with 7 + 3 like manipulating the doses or the duration, but with no significant change in the outcome. In 2017 FDA approved CPX351,a liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio, for the treatment of adults with newly diagnosed AML with myelodysplasia-related changes and therapy-related AML (t-AML). Since the approval, many trials were conducted or still ongoing in assessing the role of CPX-351 in treating different patient populations, AML subcategories or when combined with different agents. In this review, we will summarize the current role of CPX-351 in treating this largely heterogeneous disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available